Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Hypophosphatasia

In brief

The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.

Key facts

Study ID: NCT06079281
Run by: Alexion Pharmaceuticals, Inc.
People needed: 124
Starts: 2024-01-03
Expected to finish: 2028-03-29
Last updated by the study team: 2026-06-22

Who can join

Age: 12 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Diagnosis of HPP documented in the medical records
Must meet 1 of the following criteria:
Documented ALPL gene variant (pathogenic, likely pathogenic, or variant of unknown significance) from a Clinical Laboratory Improvement Amendments (CLIA) or ISO 15189 certified laboratory (Section 8.7 )
Plasma PLP above the upper limit of normal (ULN) during the Screening Period (central or local laboratory results allowed per local regulations)
Must meet 1 of the following criteria without a probably cause other than HPP:
Serum ALP activity below the age- and sex-adjusted normal range during the screening period as measured by the Central Laboratory
Two documented serum ALP activity results, at least 15 days apart, below the age- and sex-adjusted local laboratory normal range during the 24 months before the Day 1 Visit. Note: Local laboratories need to be CLIA or ISO 15189 certified, or have other local equivalent laboratory certification with Alexion's approval.
Two separate 6MWTs at below 85% of the predicted distance (for age, sex, weight, and height) during the Screening Period without a probable cause other than HPP

You may not qualify if…

History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological disorders, or any other disorders that are capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data as determined by the Investigator
Diagnosis of primary or secondary hyperparathyroidism
Hypoparathyroidism, unless secondary to HPP
Any new fracture within 12 weeks before Day 1 (excluding pseudofractures)
Planned surgical intervention which may impact the results of study assessments (in the opinion of the Investigator) during the Randomized Evaluation Period
History of allergy or hypersensitivity to any ingredient contained in ALXN1850 or the placebo comparator (Table 9)

Where it is running

Research Site — Garden City, New York, United States
Research Site — Durham, North Carolina, United States
Research Site — Columbus, Ohio, United States
Research Site — Nashville, Tennessee, United States
Research Site — Ciudad de Buenos Aires, Argentina
Research Site — Clayton, Australia
Research Site — Herston, Australia
Research Site — Parkville, Australia
Research Site — St Leonards, Australia
Research Site — Belo Horizonte, Brazil
Research Site — Brasília, Brazil
Research Site — Recife, Brazil
Research Site — Salvador, Brazil
Research Site — São Paulo, Brazil
Research Site — São Paulo, Brazil
Research Site — Calgary, Alberta, Canada
Research Site — Edmonton, Alberta, Canada
Research Site — Winnepeg, Manitoba, Canada
Research Site — Oakville, Ontario, Canada
Research Site — Trois-Rivières, Quebec, Canada
Research Site — Beijing, China
Research Site — Beijing, China
Research Site — Changsha, China
Research Site — Chengdu, China
Research Site — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.